openPR Logo
Press release

Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019

09-13-2019 03:00 PM CET | Health & Medicine

Press release from: SMI

HPAPI USA conference 2019

HPAPI USA conference 2019

SMI Reports: Exclusive interview with industry expert, Richard Arnett Manager, Industrial Hygiene, Pharmascience for the HPAPI USA conference 2019

Ahead of the 2019 HPAPI USA Conference taking place in Boston on 21st – 22nd October, SMi caught up with Richard Arnett, Manager, Industrial Hygiene, Pharmascience who is speaking on Day Two of the agenda. Richard shared his thoughts on how the industry has developed and briefly touched on what he will be discussing in October. At this year's HPAPI USA Conference, emerging manufacturing technologies will be one of the key points to be discussed, along with containment issues, disaster management, Oncology Antibody-Drug Conjugates (ADCs) and staff training procedures.

Snapshot of Richard’s Interview:

What key differences have you noticed in the last year regarding significant developments in Highly Potent APIs?

“Three main points: Higher potency, particularly for OSD products Lower ADE, often poorly soluble and tougher to clean APIs Closer scrutiny by regulatory agencies. For example Health Canada is now more closely aligned with the EMA and there’s now a more harmonised approach, with a mutual recognition agreement in place which sets the bar to the appropriate level, not just with the regs/GMP’s, but also through compliance/enforcement ensuring that the appropriate controls are in place to mitigate cross-contamination risks…”

What do you see as the greatest challenge for you to overcome personally in the Highly Potent API field currently?

“Changing the culture from traditional ‘open processes’ to closed processing with reduced reliance on PPE & thus reduced worker-product exposure risk. I often hear ‘what’s the risk – the workers are wearing respirators’– and there remains a perception that this is adequate… But what about when the airborne concentration might exceed the assigned protection factor of the respirators? Or what about the exposure risk when the respirators are removed?...”

Richard will be joined at the conference by a number of key figures in the HPAPI industry including Rakesh Dixit, Vice President of R&D Global Head, MedImmune; Vice President of R&D Translational Sciences – Biologics Safety Assessment, AstraZeneca; Janet Gould, Senior Managing Toxicologist, SafeBridge Consultants USA and many more.

For the full speaker interview, event details and speaker line-up, it is available to download at www.hpapi-usa.com/openPR6

Proudly Sponsored by BSP Pharmaceuticals | LONZA | Minakem | SafeBridge Consultants

Highly Potent Active Pharmaceutical Ingredients USA
Conference: October 21st – 22nd
Workshops: October 23rd
Venue: Sheraton Boston Hotel, USA

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 or nhoward@smi-online.co.uk

45 Curlew Street

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019 here

News-ID: 1832942 • Views: 659

More Releases from SMI

Senior US officials from fuel policy teams and combat wings to present at Milita …
SMi reports: Senior US officials will be presenting at the 21st Annual Military Airlift Air-to-Air Refuelling conference in Seville, this December Air-to-air refuelling remains a key mission multiplier, utilised extensively in Operation Inherent Resolve to extend flight times for bombing runs against ISIS. As the US Air Force explores the greater utilisation of commercial refuellers for CONUS operations to free military assets for combat and international deployment there is a critical
Senior experts to discuss Naval Mine Countermeasures at Unmanned Maritime System …
The challenge posed by potential adversary mining capabilities is real and growing. For all navies, there is only one way to completely “Take the sailor out of the minefield,” and that is to leverage unmanned technologies to hunt and destroy mines from a distance.* By embracing technological advancements in unmanned systems, such as UUVs and USVs, they could sweep large portions of the sea while minimizing the risk to sailors. For
Military Robotics and Autonomous Systems 2020 announced as a Virtual Event
SMi Reports: Due to the ongoing challenges surrounding COVID-19, Military Robotics and Autonomous Systems in September will now run as a virtual event. With the continued uncertainty surrounding large gatherings in the UK, SMi Group have made the decision to turn the 3rd annual Military Robotics and Autonomous Systems Conference on the 2nd-3rd September 2020 into a fully interactive virtual meeting. All attendance by military and government will be free of charge
04-07-2020 | Health & Medicine
SMI
Associates of Cape Cod Webinar on Recombinant Chromogenic Assay as Alternate Met …
SMi Reports: Associates of Cape Cod to host an online webinar taking place on Wednesday 29th April 2020. SMi Group is delighted to announce a free webinar led by Associates of Cape Cods on 'Recombinant Chromogenic Assay as Alternate Methods for Bacterial Endotoxins Test (BET)' taking place on 29th April 2020 at 10am EDT (3pm BST - UK time). The webinar will aim to review the global perspective on the use

All 5 Releases


More Releases for API

Tagraxofusp - API Insight, 2018
Tagraxofusp, sold under the brand name of Elzonris, is an Interleukin 3 (IL-3) conjugated truncated diphtheria toxin. It is composed of catalytic and translocation domains of diphtheria toxin fused via Met-His linker to a full-length human IL-3. Download the sample report @ https://www.pharmaproff.com/request-sample/1168 Tagraxofusp was developed by Stemline Therapeutics Inc. and was approved in December 2018, as the first therapy for blastic plasmacytoid dendritic cell neoplasm. This drug achieved approval after
Cabozantinib- API Insight, 2018
Cabozantinib, sold under the brand name of Cabometyx and Cometriq, is used for the treatment of medullary thyroid cancer and a second line treatment for renal cell carcinoma. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET. Download the sample report @ https://www.pharmaproff.com/request-sample/1164 Discovered and developed by Exelixis Inc., its side-effects include increased liver enzymes, diarrhea, low calcium, mouth sores, decreased
Tyk API Management v2.3
After months working-out in the gym, the new version of Tyk is ready to flex its muscles.   Tyk v2.3 is twice as fast, leaner, more extendable and is still available for FREE! London, United Kingdom 8th December, 2016. Tyk Technologies is pleased to announce the v2.3 release of Tyk, the popular open-source API Management platform.   Tyk v2.3 builds upon the success of previous releases. The feedback and contributions from Tyk’s thriving open source community, as well as enterprise clients, drove
Telecom API Helps Application Developers to Integrate Various API Services
Telecom API market represents an overall Application Programming Interface (API) services provided by telecom carriers, service providers and aggregators to application developers in order to create mobile applications. Telecom API helps application developers to integrate various services such as payment, voice, SMS and WebRTC into their mobile application. This helps application developers to enhance their customer experience and market their mobile applications among end-users. Telecom API provides many benefits to
Biotech API Surging Worldwide
According to a new research report by RNCOS, entitled “Global Biotech API Market Analysis”, geographies across the world are showing insurgent growth in the biotech API Industry. The US occupied more than half of the share in the global market in 2011, and is the largest producer of biotech APIs. Western European countries occupy around 15% share globally among which, the UK is the largest producer of biotechnology-based APIs. The
Global Biotech API Market Analysis
RNCOS has recently added a new Market Research Report titled, “Global Biotech API Market Analysis” to its report gallery. Biotech APIs contribute a very low share in the global API market with synthetic API’s accounting for majority of the formulations. However, with the revolutionary growth in the biopharmaceutical industry and gaining applications of biotech drugs, biotech API’s are sure to see a highly prospective market in the future. As per our